Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Eunsol Yang, Hyounggyoon Yoo, In-Jin Jang, Kyung-Sang Yu & SeungHwan Lee. (2021) Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study. Drug Design, Development and Therapy 15, pages 651-658.
Read now
Read now
Eunwoo Kim, Kyoung Ryun Park, In-Jin Jang, Kyung-Sang Yu & SeungHwan Lee. (2019) A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects. Drug Design, Development and Therapy 13, pages 3879-3885.
Read now
Read now
Hee Youn Choi, Hyeong-Seok Lim, Yo Han Kim, Hae Sun Jeon, Mi Jo Kim, Shi Hyang Lee, Jong Hyuk Jung, Young Kyoung Lee, Hyun Jeong Kim & Kyun-Seop Bae. (2015) Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. Current Medical Research and Opinion 31:2, pages 229-241.
Read now
Read now
Articles from other publishers (13)
Sae Im Jeong, Yun Kim, Jae Jin Nah, Wan Huh, In‐Jin Jang, Jun Gi Hwang & SeungHwan Lee. (2023) Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium–glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults. British Journal of Clinical Pharmacology 89:6, pages 1780-1788.
Crossref
Crossref
Yaochen Xie, Qian Zhou, Qiaojun He, Xiaoyi Wang & Jincheng Wang. (2023) Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition. Acta Pharmaceutica Sinica B 13:6, pages 2383-2402.
Crossref
Crossref
Simon G. Wong & Shuguang Ma. 2023. Overcoming Obstacles in Drug Discovery and Development. Overcoming Obstacles in Drug Discovery and Development
137
174
.
Deep Dutta, Anshita Agarwal, Indira Maisnam, Rajiv Singla, Deepak Khandelwal & Meha Sharma. (2021) Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis. Endocrinology and Metabolism 36:2, pages 374-387.
Crossref
Crossref
Namyi Gu, Sang-In Park, Hyewon Chung, Xuanyou Jin, SeungHwan Lee & Tae-Eun Kim. (2020) Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. Translational and Clinical Pharmacology 28:1, pages 17.
Crossref
Crossref
Naina Mohamed Pakkir Maideen. (2019) Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump. World Journal of Meta-Analysis 7:4, pages 156-161.
Crossref
Crossref
Ignacio Conde-Carmona, Sandra García-Medina, Juan M. Jiménez-Vargas, Alberto Martínez-Muñoz & Sung-Hack Lee. (2018) Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers. Clinical Therapeutics 40:10, pages 1729-1740.
Crossref
Crossref
Yong-Soon Cho, Shi Hyang Lee, Hyeong-Seok Lim & Kyun-Seop Bae. (2018) Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects. Journal of Korean Medical Science 33:41.
Crossref
Crossref
C. F. Deacon & H. E. Lebovitz. (2016) Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism 18:4, pages 333-347.
Crossref
Crossref
Sung-Ho KimJung-Hwa YooWoo Je LeeCheol-Young Park. (2016) Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. Diabetes & Metabolism Journal 40:5, pages 339.
Crossref
Crossref
Gwon-Soo JungJae-Han JeonMi Sun ChoeSung-Woo KimIn-Kyu LeeMi-Kyung Kim & Keun-Gyu Park. (2016) Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice. Diabetes & Metabolism Journal 40:3, pages 211.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
Crossref
J.H. Shon, N. Kim, S.J. Park, M.K. Oh, E.Y. Kim, S.H. Lee, Y.H. Kim & J.G. Shin. (2014) Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444). Diabetes, Obesity and Metabolism 16:10, pages 1028-1031.
Crossref
Crossref